Christopher Cline
Chief Financial OfficerMr. Christopher Cline, also known as Chris, CFA, is Chief Financial Officer at Travere Therapeutics, Inc. since August 31, 2022. He served as Senior Vice President of Investor Relations and Corporate Communications at Travere Therapeutics, Inc. since November 2020 and served as its Investor Relations and Corporate Communications since April 2017 until September 2019. Mr. Cline has industry experience in Investor Relations, corporate communications, and financial strategy, planning and analysis to the Chief Financial Officer position. Since joining Travere in 2014, he has been responsible for leading engagement with the investment community, as well as building a developed corporate communications infrastructure. He has served as a Member of the Travere senior leadership team since 2019. Prior to Travere, he was a Member of the global Investor Relations group at Elan Corporation, plc, and the financial planning and analysis group at Phase Forward. Mr. Cline served as Vice President of Investor Relations and Corporate Communications at Retrophin, Inc. Mr. Cline served as Senior Director of Investor Relations at Retrophin, Inc. Mr. Cline is a CFA charter holder and holds B.S.B.A in Finance from the Williams College of Business at Xavier University in the year 2002.
Positions
- Company NameTravere Therapeutics, Inc.Stock CodeTVTXPositionChief Financial OfficerColleagues
- EMEric M. DubePresident, CEO & Director
- GAGary A. LyonsIndependent Chairman of the Board
- WEWilliam E. RoteChief Research Officer
- PHPeter HeermaChief Commercial Officer
- JIJula InrigExecutive VP, Head of Research & Development and Chief Medical Officer
- JAJeffrey A. MecklerIndependent Director
- TPTimothy P. CoughlinIndependent Director
- JAJohn A. OrwinIndependent Director
